Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO WCGIC 2022 | Pooled analysis from the CRICKET and CAVE trials for the treatment of mCRC

Erika Martinelli, MD, PhD, University of Campania Luigi Vanvitelli, Caserta, Italy, discusses the findings from an analysis of data pooled from the CRICKET (NCT02296203) and CAVE (NCT04561336) trials. The positive results of the rechallenge third-line treatment with cetuximab, such as the resulting median progression-free survival (PFS) of 3.9 months and median overall survival (OS) of 16.9 months, are discussed. This interview took place at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer (ESMO WCGIC) 2022 in Barcelona, Spain.